Product news from the 09/26/06 News Brief

Share this article:
Allergan, maker of Botox cosmetic (Botulinum Toxin Type A), today announced it is launching its “next-generation” hyaluronic acid dermal filler products, Juvederm Ultra and Juvederm Ultra Plus. The launch will take place through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January 2007. Allergan will begin accepting physician pre-orders for the products on Nov.1 via its nationwide sales force. The FDA approved Connetics’ Verdeso (desonide) foam for the treatment of mild-to-moderate atopic dermatitis. Verdeso, previously referred to as Desilux, is a low-potency topical steroid. Connetics expects to begin marketing Verdeso to physicians in the fourth quarter of 2006 in 50g and 100g trade unit sizes. The FDA has approved new formulation of Alcon’s Travatan Z opthalmic solution for the expanded indication of reduction of elevated intraocular pressure. The drug is recommended for patients with open-angle glaucoma or ocular hypertension, who are intolerant of or not responsive enough to other medications.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.